First indication of bankruptcy is NOT being able to meet payroll or pay debts. Paying management is stock is clearly demonstrates lack of cash. Still haven't resolved the issue of $45 million in Samsung past deb debt and $55 million in vulture fund debt.
Management gets a chose of leaving the company or take the stock. Don't think CYDY on the resume will help them find a new job. Especially SK who is very likely under SEC/DOJ investigation.
NASH results are certainly not going to show much potential. The 700 mg was no better than 350 mg. And 350 mg. is mediocre at best -- 16-20% fat reduction vs. the 45% of the leading NASH candidates. No BP will want to partner on a mediocre results for a very long an expensive Ph 3 trial. Only a small % of biotechs get partnership or buyouts - CYDY has waaay to much baggage to pass any due diligence in the first place.
They still have no cash for any new trials or to pay their debts and the cash raises are just to keep the lights on. A pretty bleak future.
News 
Market Data 
Discover 
